Fampridine has been approved for use on the NHS in England, marking the first time the medication has been made available through the health service in the country. The drug functions as a signal booster, enhancing electrical messages that travel through damaged nerve cells and help control muscle movement. Up to 5,000 people annually in England are expected to benefit from the treatment, according to officials.
Multiple sclerosis damages the protective covering around nerve cells, which impairs the ability of nerves to carry electrical signals from the brain to other parts of the body. This disruption particularly affects the precise muscle control required for walking. Clinical trials demonstrated that approximately four in 10 people taking fampridine experienced improvements in their walking speed and the duration they could walk for. These gains, while modest for some patients, can meaningfully impact daily functioning and independence.
The drug had previously been rejected for NHS use in England on cost-effectiveness grounds, though it became available in Wales, Scotland, and Northern Ireland. NHS officials noted that walking difficulties significantly affect the freedom and independence of people living with multiple sclerosis. Prof Frankie Swords, the NHS national medical director, characterized the approval as potentially life-changing for patients, as even modest improvements in mobility could enable greater household movement, increased confidence when going out, and enhanced independence.
More than 120,000 people live with multiple sclerosis in England, though eligibility for fampridine will be determined by the extent of walking difficulties. Patients will receive a trial period of up to a month, and only those demonstrating clear benefit will continue the medication. The MS Society expressed support for the decision, suggesting the drug could enable people to maintain employment and live more independently. Current NHS support for multiple sclerosis patients includes physiotherapy and walking aids.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI